Smith Karen L. is a director of Aurinia Pharmaceuticals Inc.
Person profile
Roles
Address
Dublin L2 4, Ireland
Employees
SEC CIK
Latest filings (excl ownership)
No filings
Latest ownership filings
4
SANGAMO THERAPEUTICS, INC
6 Jun 24
4
Aurinia Pharmaceuticals Inc.
21 Aug 23
3
Aurinia Pharmaceuticals Inc.
21 Aug 23
4
Talaris Therapeutics, Inc.
14 Jun 23
4
SANGAMO THERAPEUTICS, INC
5 Jun 23
4
Quince Therapeutics, Inc.
2 Feb 23
4
Talaris Therapeutics, Inc.
13 Jun 22
4/A
Cortexyme, Inc.
27 May 22
4
ANTARES PHARMA, INC.
26 May 22
4
Cortexyme, Inc.
23 May 22
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Jun 24 | SGMO Sangamo Therapeutics | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 77,100 |
4 Jun 24 | SGMO Sangamo Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5676 | 50,000 | 28.38 k | 50,000 |
18 Aug 23 | AUPH Aurinia Pharmaceuticals | Stock Option Common Stock | Grant | Acquire A | No | No | 9.49 | 28,959 | 274.82 k | 28,959 |
18 Aug 23 | AUPH Aurinia Pharmaceuticals | RSU Common Stock | Grant | Acquire A | No | No | 0 | 17,913 | 0.00 | 17,913 |
13 Jun 23 | TRML Tourmaline Bio | Stock Option Common Stock | Grant | Acquire A | No | No | 2.54 | 20,500 | 52.07 k | 20,500 |
1 Jun 23 | SGMO Sangamo Therapeutics | Common Stock | Grant | Acquire A | No | No | 0 | 13,900 | 0.00 | 52,100 |
1 Jun 23 | SGMO Sangamo Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 1.11 | 27,750 | 30.80 k | 27,750 |